ORG-12962 is a pyridinylpiperazine drug developed by Organon, which acts as a potent and selective agonist for the 5-HT2 receptor family, with highest affinity at 5-HT2C and lowest at 5-HT2B subtypes. It was developed as a potential anti-anxiety drug, but was discontinued from human trials after tests in a public speaking challenge showed that its anti-anxiety effects were accompanied by side effects such as dizziness and a "spacey" feeling, which were attributed to poor selectivity in vivo over the hallucinogenic 5-HT2A receptor.

See also

  • 2C-B-PP
  • 2,3-Dichlorophenylpiperazine
  • 3-Chloro-4-fluorophenylpiperazine
  • CPD-1
  • ORG-37684
  • Quipazine

References



DIN EN 1295222002 Watertube boilers and auxiliary installations

DIN EN 129622001 Adhesives Determination of elastic behaviour of

En 129526 PDF PDF

DIN EN 149622006 Water quality Guidance on the scope and selection

DIN EN 6126221995 DE Medizinische elektrische Geräte Merkmale von